Thrombotic microangiopathy following haematopoietic stem cell transplant
Thrombotic microangiopathy following haematopoietic stem cell transplant
Thrombotic microangiopathy is a potentially lethal complication of haematopoietic stem cell (bone marrow) transplantation. The pathophysiology is incompletely understood, although endothelial damage appears to be central. Platelet activation, neutrophil extracellular traps and complement activation appear to play key roles. Diagnosis may be difficult and universally accepted diagnostic criteria are not available. Treatment remains controversial. In some cases, withdrawal of calcineurin inhibitors is adequate. Rituximab and defibrotide also appear to have been used successfully. In severe cases, complement inhibitors such as eculizumab may play a valuable role. Further research is required to define the pathophysiology and determine both robust diagnostic criteria and the optimal treatment.
Acute kidney injury, Complement, Hematopoietic stem cell transplant, Neutrophil extracellular traps, Thrombotic microangiopathy
1489-1500
Seaby, Eleanor G.
ec948f42-007c-4bd8-9dff-bb86278bf03f
Gilbert, Rodney D.
c69c5b99-2a15-4502-acd8-36b254d42601
1 September 2018
Seaby, Eleanor G.
ec948f42-007c-4bd8-9dff-bb86278bf03f
Gilbert, Rodney D.
c69c5b99-2a15-4502-acd8-36b254d42601
Seaby, Eleanor G. and Gilbert, Rodney D.
(2018)
Thrombotic microangiopathy following haematopoietic stem cell transplant.
Pediatric Nephrology, 33 (9), .
(doi:10.1007/s00467-017-3803-4).
Abstract
Thrombotic microangiopathy is a potentially lethal complication of haematopoietic stem cell (bone marrow) transplantation. The pathophysiology is incompletely understood, although endothelial damage appears to be central. Platelet activation, neutrophil extracellular traps and complement activation appear to play key roles. Diagnosis may be difficult and universally accepted diagnostic criteria are not available. Treatment remains controversial. In some cases, withdrawal of calcineurin inhibitors is adequate. Rituximab and defibrotide also appear to have been used successfully. In severe cases, complement inhibitors such as eculizumab may play a valuable role. Further research is required to define the pathophysiology and determine both robust diagnostic criteria and the optimal treatment.
Text
Seaby-Gilbert2018_Article_ThromboticMicroangiopathyFollo
- Version of Record
More information
Accepted/In Press date: 1 September 2017
e-pub ahead of print date: 9 October 2017
Published date: 1 September 2018
Keywords:
Acute kidney injury, Complement, Hematopoietic stem cell transplant, Neutrophil extracellular traps, Thrombotic microangiopathy
Identifiers
Local EPrints ID: 422782
URI: http://eprints.soton.ac.uk/id/eprint/422782
ISSN: 0931-041X
PURE UUID: fd950d60-557d-4f3c-854f-cd11b03420a1
Catalogue record
Date deposited: 06 Aug 2018 16:30
Last modified: 18 Apr 2024 01:54
Export record
Altmetrics
Contributors
Author:
Eleanor G. Seaby
Author:
Rodney D. Gilbert
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics